Literature DB >> 1353961

Total prevention of the development of in vitro tolerance to organic nitrates. Experiments with antioxidants.

R A Yeates1, M Schmid.   

Abstract

The nearly total inhibition of development of pharmacological tolerance to an organic nitrate is reported here for the first time. The development of in vitro tolerance in the rabbit aorta to isosorbide-5-mononitrate (CAS 87-33-2) was potently inhibited by five structurally unrelated antioxidants--diaminodurol, ascorbic acid, potassium sulphite, pyrogallol and quercetin. Diaminodurol, ascorbic acid and potassium sulphite decreased, but quercetin increased, the spasmolytic activity of isosorbide-5-mononitrate. Diaminodurol, potassium sulphite, quercetin and ascorbic acid potently inhibited the spasmolytic activity of nitric oxide (NO). Quercetin also inhibited the development of in vitro tolerance to glyceryl trinitrate. It is suggested that tolerance to organic nitrates is the result of biochemical damage caused by a reactive intermediate such as NO. To test this possibility directly the effect of pretreatment with NO on the spasmolytic activity of glyceryl trinitrate (CAS 55-63-0) was examined. This pretreatment produced a small but significant tolerance to glyceryl trinitrate and to SIN-1 (3-morpholinosydnone imine), which also acts through guanylate cyclase. There was no effect on the activity of the unrelated vasodilators nitrendipine and theophylline. It is concluded that the reaction between NO and soluble quanylate cyclase is a real but minor cause of tolerance to organic nitrates. Other possible mechanisms of tolerance development are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353961

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Mechanisms of nitric oxide generation from nitroglycerin and endogenous sources during hypoxia in vivo.

Authors:  Per Agvald; L Christofer Adding; Andreas Artlich; Magnus G Persson; Lars E Gustafsson
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles.

Authors:  B Mayer; M Beretta
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

3.  The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363.

Authors:  M Civelli; M Giossi; P Caruso; R Razzetti; M Bergamaschi; S Bongrani; A Gasco
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione.

Authors:  Wayne Kaesemeyer; Tatsiana Suvorava
Journal:  Am J Cardiovasc Drugs       Date:  2021-03-22       Impact factor: 3.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.